Evidence map›Paper›PMID 38530495›Full record

ArticleApplied microbiology and biotechnology2024

Effects of process intensification on homogeneity of an IgG1:κ monoclonal antibody during perfusion culture.

George Liang, Chikkathur N Madhavarao, Caitlin Morris, Thomas O'Connor, Muhammad Ashraf, Seongkyu Yoon

Abstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

George Liang *Division of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA.
Chikkathur N Madhavarao *Division of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA. chikkathur.madhavarao@fda.hhs.gov.ORCID http://orcid.org/0000-0003-3392-1159
Caitlin MorrisDivision of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA.
Thomas O'ConnorDivision of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA.
Muhammad AshrafDivision of Product Quality Research, OTR/OPQ, CDER/FDA, Silver Spring, MD, USA.
Seongkyu YoonDepartment of Chemical Engineering, University of Massachusetts Lowell, Lowell, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pharmaceutical industry employs various strategies to improve cell productivity. These strategies include process intensification, culture media improvement, clonal selection, media supplementation and genetic engineering of cells. However, improved cell productivity has inherent risk of impacting product quality attributes (PQA). PQAs may affect the products' efficacy via stability, bioavailability, or in vivo bioactivity. Variations in manufacturing process may introduce heterogeneity in the products by altering the type and extent of N-glycosylation, which is a PQA of therapeutic proteins. We investigated the effect of different cell densities representing increasing process intensification in a perfusion cell culture on the production of an IgG1-κ monoclonal antibody from a CHO-K1 cell line. This antibody is glycosylated both on light chain and heavy chain. Our results showed that the contents of glycosylation of IgG1-κ mAb increased in G0F and fucosylated type glycans as a group, whereas sialylated type glycans decreased, for the mAb whole protein. Overall, significant differences were observed in amounts of G0F, G1F, G0, G2FS1, and G2FS2 type glycans across all process intensification levels. G2FS2 and G2 type N-glycans were predominantly quantifiable from light chain rather than heavy chain. It may be concluded that there is a potential impact to product quality attributes of therapeutic proteins during process intensification via perfusion cell culture that needs to be assessed. Since during perfusion cell culture the product is collected throughout the duration of the process, lot allocation needs careful attention to process parameters, as PQAs are affected by the critical process parameters (CPPs). KEY POINTS: • Molecular integrity may suffer with increasing process intensity. • Galactosylated and sialylated N-glycans may decrease. • Perfusion culture appears to maintain protein charge structure.

Indexed as

Antibodies, MonoclonalImmunoglobulin GAnimalsCHO CellsCricetinaeCricetulusPerfusionPolysaccharidesAntibodies, MonoclonalImmunoglobulin GPolysaccharidesCHO-K1 cell lineIsoelectric pointMicro heterogeneityN-glycosylationProtein integrityVRC01 mAb

Identifiers

PMID38530495
PMCPMC10965650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.